From the New to The Street’s Nasdaq Marketsite studio, David Luci, the President/CEO at Acurx Phamaceuticals, Inc. (NASDAQ: ACXP) ($ACXP), talks with TV Host Monica Malpass about the Company’s clinical biopharmaceutical business developing a new class of antibiotics for life-threatening bacterial infections. David explains the Company’s R&D pipeline of first-in-class novel clinical stage and early-stage antibiotic candidates that target Gram-positive bacteria caused by Clostridioides difficile Infections (CDI) (C. diff), MRSA (methicillin-resistant Staphylococcus aureus), and DRSP (Drug-resistant Streptococcus Pneumoniae). Hospital patients and nursing home residents are the most considerable percentage of those infected with these types of bacteria. A recent US Government report stated that over 52% of hospital patients became infected with MRSA. ACXP’s novel Ibezapolstat drug for C. diff show restoration of a healthy microbiome in patients and is currently in an FDA Phase 2b trial. The Company expects to pursue a Phase 3 trial and believes it can do so without a huge cost. The Company’s executive team consists of well know industry leaders with contacts and resources that bring vast talents to operations at ACXP. The interview airs on Newsmax, episode 459, April 22, 2023, at 3:30 PM ET, and the FOX Business Network, episode 460, April 24, 2023, at 10:30 PM PT. The on-screen QR code is available during the show; download or visit Acurx Pharmaceticals, Inc. – https://www.acurxpharma.com/.
To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv
Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet
Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/
Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/
Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet
About New to the Street: https://newtothestreet.com/
Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list